Amphista Therapeutics Raises $7.5m Series A Round to Advance Targeted Protein Degradation Assets in Cancer
- Tuesday, April 7, 2020, 7:03
- Finance
- Add a comment
GLASGOW, Scotland, April 7, 2020 /PRNewswire/ — Amphista Therapeutics, a biopharmaceutical company creating first-in-class cancer therapeutics that harness the body’s natural processes to selectively and efficiently degrade and remove disease causing proteins, today announced the closing…
About the Author
adminasapcorp has written 41552 stories on this site.